NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - November 13, 2007) - An article published in a recent edition of the peer review journal Expert Opinion, Vol. 16, No. 8, reveals the compound NV-52, developed by Novogen Limited (ASX: NRT) (NASDAQ: NVGN), may be useful for the maintenance of remission in inflammatory bowel disease (IBD).
